Cardiopulmonary Exercise Testing in the Age of New Heart Failure Therapies: Still a Powerful Tool?

ABSTRACT:

Background

New therapies with prognostic benefits have been recently introduced in heart failure with reduced ejection fraction (HFrEF) management. The aim of this study was to evaluate the prognostic power of current listing criteria for heart transplantation (HT) in an HFrEF cohort submitted to cardiopulmonary exercise testing (CPET) between 2009 and 2014 (group A) and between 2015 and 2018 (group B).

Methods

Consecutive patients with HFrEF who underwent CPET were followed-up for cardiac death and urgent HT.

Results

CPET was performed in 487 patients. The composite endpoint occurred in 19.4% of group A vs. 7.4% of group B in a 36-month follow-up. Peak VO₂ (pVO₂) and VE/VCO₂ slope were the strongest independent predictors of mortality

SUBMITTER: Garcia Bras P 

PROVIDER: S-EPMC10452308 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature